Fairchem OrganicQ1 FY25

Fairchem Organic Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹665.4P/E: 34.2Market Cap: ₹838 Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Fairchem Organics showed a 3% year-on-year revenue growth in Q1 FY25, with Rs. 165 crores in revenue.
  • EBITDA grew significantly by 86% year-on-year, indicating improving profitability.
  • Isostearic acid, a novel high-value product, is expected to drive future growth, with exports to Europe and US already underway.
  • Customer stability testing for Isostearic acid takes 3-6 months; approvals from 15-20 new customers are in progress.
  • Full capacity utilization for Isostearic acid (500 MT per quarter) is targeted by December 2024.
  • New product launches from novel raw materials are in pilot stages, with potential commercial launch around Q4 FY25, though timelines are tentative.
  • Management remains optimistic about Isostearic acid growth, focusing efforts primarily on this product segment.
  • Total sales volumes remain steady, with Q1 FY25 at 16,728 MT, comparable to previous quarters.

See what Fairchem Organic management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any current or planned fundraising through debt or equity in the transcript.
  • The management did not discuss any plans for raising capital during the Q1 FY 2025 earnings call.
  • The focus was primarily on operational highlights, sales performance, and product development, especially the Isostearic acid business.
  • Any future updates, including on fundraising, may be communicated in subsequent con-calls or announcements once decisions are made.
  • Investors are encouraged to reach out to the company or Investor Relations advisors for further queries.

See what Fairchem Organic management said on order book — free account, 30 seconds.

Capex plans

Yes
  • No specific mention of current or future capex, capital investment, or strategic investment was made during the call.
  • The company is focusing on developing and stabilizing the Isostearic acid business, which involved startup losses earlier but is now operational and exporting.
  • Work is ongoing at the pilot plant level for new products derived from new raw materials, with no definite timeline yet for commercial launch; updates will be provided after pilot runs.
  • The company is prioritizing Isostearic acid development due to its strong potential but did not disclose any explicit capital expenditure plans related to this or other expansions.

Track Fairchem Organic — get its next earnings analysis in your feed

How does Fairchem Organic rank vs peers in ?

Pro feature
ThisFairchem Organic
Rev 3Mar 3

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →